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Summary: A number of methoxy-substituted 7 J i b ^^-tetrahydro-o/Z-dibenzo-
laj/lquinolizines with short alkyl groups in position 6 or 12 were synthesized by the 
Bischler-Napieralski reaction using the appropriate starting material followed by a 
second ring closure reaction involving a base-generated benzyne intermediate. The 
methoxy functions in positions 2 or 3 and 9 were cleaved with B B r 3 and the free 
hydroxy groups converted into the acetates. The enantiomers of two of these deriva-
tives were separated by liquid chromatography on triacetylcellulose. Compounds with 
alkyl substituents bind strongly to the estrogen receptor except those with a dis-
orientation at the central ring connection. The R B A values ranged from 2.2-10.8 
(17ß-estradiol: R B A = 100). There was no major difference in binding between the 
(+) and (—)-enantiomers. The 3,9-diacetoxy-6-alkyl derivatives also showed binding 
affinity for the progesterone receptor (RBA: 1.2-3.1). The 2,9-diacetoxy-
dibenzoquinolizines trans-6\ and -6m with ethyl and propyl respectively in position 12 
strongly inhibited the growth of hormone-sensitive MCF-7 breast cancer cells at 
concentrations of 10"6 M and higher but were inactive in hormone-independent M D A -
MB 231 breast cancer cells. Preliminary tests with hormone-dependent M X T mouse 
mammary tumors as model showed that these compounds have also antineoplastic 
activity in vivo. Derivative trans-6\ at a dose of 20 mg/kg body weight, administered 3 
times/week, inhibited the growth of these tumors by 78% (tamoxifen: 76% inhibi-
tion). Studies on the estrogenic and antiestrogenic properties of these agents in mice 
revealed that they are rja,ixed agonists/antagonists with strong antiestrogenic activity at 
low doses but significant estrogenic effects at higher doses. 
Key words: cytostatic activity/dibenzo[tf,/]quinolizines/estrogen receptor affinity/ 
synthesis 
Introduction 
Tetracyclic systems based on the isoquinoline structure such as indolo[2,7-fl]isoquinoline 
(Polossek et al., 1992; Ambros et al., 1989) and dibenzo[ö,g]-quinolizin-8-ones (von 
Angerer et al., 1992) have been shown to possess cytostatic activity. When acetoxy 
groups were introduced into appropriate positions of the benzene rings in these structures, 
significant binding affinities for estrogen receptors were observed. The receptor binding 
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can be improved by the introduction of short alkyl groups as a result of an enhanced 
lipophilicity in the central part of the molecule. Endocrine studies revealed that some of 
these derivatives can be considered as antiestrogens and might be useful for the endo-
crine therapy of hormone-dependent malignancies such as mammary and endometrium 
carcinomas. 
In order to evaluate the therapeutic potential of these tetracyclic systems we extended 
our studies to acetoxy-substituted TJlbj^J^-tetrahydro-oH-dibenzo^/jquinol izines 
with alkyl substituents at C-6 and C-12 (Structures 1). The main differences between this 
structure and the series of compounds we studied previously are a basic nitrogen and a 
tetrahedral carbon adjacent to the nitrogen which gives rise to two different orientations 
of the ring connection in the quinolizidine moiety which can be discriminated when a 
substituent at C-12 is present. In this report, we describe the syntheses of a number of 
tetrahydro-6//-dibenzo[a,/]quinolizines with acetoxy groups in positions 2 (3) and 9 and 
short alkyl chains either at C-6 or at C-12, their binding affinities for calf uterine estrogen 
and progesterone receptors, their cytostatic activity in human breast cancer cells, and 
their endocrine properties in the mouse uterine weight test. 
Materials and methods 
Melting points (m.p.) were determined on a Büchi 510 apparatus and are uncorrected. 
Elemental analyses were performed by Mikroanalytisches Laboratorium, University of 
Regensburg. xYi N M R spectra were obtained on a Varian E M 390 and a Bruker W M 250 
spectrometer and are consistent with the assigned structures. 
[2,4,6,7- 3H(N)]Estradiol (110 Ci/mmol) was obtained from New England Nuclear 
(Dreieich, Germany), [ 3 H]Org 2058 ((16a-ethyl)-21-hydroxy-19-norpregn-4-en-3,20-
dione) from Amersham, Braunschweig, Germany. Hormones and biochemicals were 
purchased from Sigma (München, Germany). T E A [Tris buffer (10 mM, p H 7.4) 
supplemented with E D T A (1.5 mM) and N a N 3 (3 mM)] was used as buffer. 
General procedure for the synthesis of the phenylpropionic acid phenethylamides 3a-m 
Phenylpropionic acid 2 (38.6 mmol) (Seidl, 1990) was dissolved in a threefold excess of 
S O C l 2 . The reaction was started by addition of a few drops of D M F at room tempera-
ture and completed by heating at 60°C until the gas evolution ceased. The excess of 
S O C l 2 was removed in vacuo. The crude acid chloride was dissolved in dry C H 2 C 1 2 (40 
ml) and added slowly to a mixture of the respective phenylethyl amine 1 (38.6 mmol) and 
triethylamine (38.6 mmol) in 40 ml of C H 2 C 1 2 . After stirring for 1 h at room tempera-
ture, the mixture was poured into 2N H C l and extracted with C H 2 C 1 2 . The organic layer 
R1, R2 = H, OCOCH3 
R3, R4 = H, CH 3 > C 2 H 5 , C 3 H 7 
Structures 1 
Reagents 
Table I 3-(Brom-methoxyphenyl)-N-[2-(3-methoxyphenyl)ethyl]propionic acid amides 3 
Compound R1 R2 R3 R4 X1 X2 Formula" m.p.b (°C) 
3a O C H 3 H H H H Br C 1 9 H 2 2 B r N 0 3 96 
3b H O C H 3 H H Br H C 1 9 H 2 2 B r N 0 3 112 
3c O C H 3 H C H 3 H H Br C 2 0 H 2 4BrNO 3 91 
3d H O C H 3 C H 3 H Br H C 2 0 H 2 4 B r N O 3 94 
3e O C H 3 H C 2 H 5 H H Br C 2 1 H 2 6 B r N 0 3 74 
3f H O C H 3 C 2 H 5 H Br H C 2 1 H 2 6 B r N 0 3 47.5 
3g O C H 3 H C 3 H 7 H H Br C 2 2 H 2 8 B r N 0 3 72 
3h H O C H 3 C 3 H 7 H Br H C 2 2 H 2 8 B r N 0 3 oil 
3i O C H 3 H H C H 3 H Br C 2 0 H 2 4 B r N O 3 70-72 
3k H O C H 3 H C H 3 Br H C 2 0 H 2 4 B r N O 3 113 
31 O C H 3 H H C 2 H 5 H Br C 2 1 H 2 6 B r N 0 3 77.5 
3m O C H 3 H H C3H7 H Br C 2 2 H 2 8 B r N 0 3 57 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Recrystallized from EtOAc/Et 2 0 mixtures 
was dried and the solvent evaporated. The residues were purified by crystallization from 
appropriate solvents or by Kugelrohr distillation. Yields were in the range 70-90%. M . p . 
are reported in Table I. 
General procedure for the synthesis of 1,2,3,4-tetrahydro-l-(phenylethyl)isoquinolines 
4a-m 
A mixture of the phenylpropionic acid amide 3 (46 mmol) in 50 ml of dry M e C N and 12 
ml of P O C I 3 was refluxed for 3 h under nitrogen. The volume of the mixture was 
reduced to 15 ml in vacuo. In the refrigerator, the product usually crystallized; some-
times a small volume of dry E t 2 0 had to be added. The crystals were separated by 
filtration and washed with ice-cold dry acetone. A n aqueous solution of the crystals was 
made alkaline with N a O H (40%) and extracted with C H 2 C 1 2 . After drying, the organic 
solvent was removed in vacuo to give the dihydroisoquinoline as an oily residue. 
Without further purification, 16.3 mmol of the dihydroisoquinoline was dissolved in 
M e O H (70 ml). A t 0°C, 2 g of N a B H 4 was added in small portions with stirring. Stirring 
was continued for 1 h at 0°C, 30 min at room temperature, and 30 min with boiling under 
reflux. The volume was reduced to 10 ml. After addition of 80 ml of water, the mixture 
was extracted with C H 2 C 1 2 . The organic layer was washed with water and dried. The 
residue obtained after evaporation of the solvent was purified by chromatography ( S i 0 2 ; 
E t O A c ) . Solid products were crystallized from E t 2 0 , oils were distilled in vacuo. Yields 
were 80-90%. M . p . are reported in Table II. 
General procedure for the synthesis of 7,llb,12,13-tetrahydro-methoxy-6H-
dibenzo[a,f]quinolizines 5a-m 
A solution of the bromotetrahydro(phenylethyl)isoquinoline 4 (12.6 mmol) in 50 ml of 
D M S O was added slowly to a solution of sodium methylsulfinylmethanide prepared from 
2.5 g (84 mmol) of N a H (80% in oil dispersion) and 50 ml of D M S O . After stirring for 
Table II l,2,3,4,-Tetrahydro-6-methoxy-l-(phenylethyl)isoquinolines 4 
M,rov ....... II 3 ^ 
Compound R1 R2 R3 R4 X1 X2 Formula* m.pb (°C) 
4a O C H 3 H H H H Br C 1 9 H 2 2 B r N 0 3 76.5 
4b H O C H 3 H H Br H C 1 9 H 2 2 B r N 0 3 oil 
4cc O C H 3 H C H 3 H H Br C 2 0 H 2 4 B r N O 3 95-96 
4d H O C H 3 C H 3 H Br H C 2 0 H 2 4 B r N O 3 oil 
4ec O C H 3 H Q H 5 H H Br C 2 1 H 2 6 B r N 0 3 69 
4f H O C H 3 Q H 5 H Br H C 2 1 H 2 6 B r N 0 3 oil 
4gc O C H 3 H C 3 H 7 H H Br C 2 2 H 2 8 B r N 0 3 71.5 
4h H O C H 3 C 3 H 7 H Br H C 2 2 H 2 8 B r N 0 3 oil 
4id O C H 3 H H C H 3 H Br C 2 0 H 2 4 B r N O 3 oil 
4kd H O C H 3 H C H 3 Br H C 2 0 H 2 4 B r N O 3 oil 
41d O C H 3 H H Q H 5 H Br C 2 1 H 2 6 B r N 0 3 oil 
4md O C H 3 H H C 3 H 7 H Br C 2 2 H 2 8 B r N 0 3 oil 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
bRecrystallized from E t 2 0 
c Predominantly one diastereomer (95%) 
dMixture of diastereomers, ratio approximately 7:3 
12 h, the mixture was poured into 400 ml of ice water containing an excess of N H 4 C 1 and 
extracted with C H 2 C 1 2 . The organic layer was washed with water and saline. After 
drying ( N a 2 S 0 4 ) and evaporation of the solvent, an oil was obtained. After chromato-
graphy ( S i 0 2 ; C H C 1 3 / E t 2 0 19:1) solid products were crystallized from M e O H and oils 
were distilled. Diastereomeric mixtures 5i-m were separated by an additional chroma-
tography ( S i 0 2 ) with a different solvent system ( C H C 1 3 / E t 2 0 9:1). Yields and m.p. are 
reported in Table III. 
General procedure for the synthesis of acetoxy-7, lib, 12,13-tetrahydro-6H-
dibenzo[a,f]quinolizines 6a-m 
B B r 3 (0.42 ml) was added to a solution of methoxy-dibenzoquinolizine 5 (0.65 mmol) in 
15 ml of dry C H C 1 3 at 0°C. After stirring for 10 min at 0°C and 10 min at room 
temperature, the mixture was refluxed for 2 h and stirred at room temperature for 12 h. 
With cooling, 15 ml of dry M e O H were added. After evaporation of the solvent, dry 
acetone was added to crystallize the product. The crystals were separated by filtration 
and dried. 
Under nitrogen, the crystals were heated in a mixture of A c 2 0 (12 ml) and 2 drops of 
pyridine until a homogeneous solution was obtained. After stirring for additional 2 h, the 
solution was poured into ice-water and neutralized with N a O H (40%). The aqueous 
phase was extracted with C H 2 C 1 2 . After drying, the organic solvent was evaporated in 
vacuo. The residue was purified by chromatography ( S i 0 2 ; C H C 1 3 / E t 2 0 9:1). The 
yields ranged from 60-70%. M . p . are given in Table I V , N M R data in Table V . 
Chromatographic separation of the enantiomers of 61 and 6m 
The enantiomers of 61 and 6m were separated semipreparatively by liquid chromato-
graphy on triacetylcellulose (20-30 |xm)(Koller etal., 1983) with E t O H as eluent at 22°C 
Table III 7,llb,12,l3-Tetrahydro-dimethoxy-6f/-dibenzo[ö,/]quinolizines 5 
IL Js. n y 
Compound fl7 R2 R3 R4 % Yield Formula* m.p h (°C) 
5a O C H 3 H H H 64 C 1 9 H 2 1 N 0 2 151 
5b H O C H 3 H H 60 C 1 9 H 2 1 N 0 2 oil 
5a O C H 3 H C H 3 H 51 C 2 0 H 2 3 N O 2 151 
5d H O C H 3 C H 3 H 54 C 2 0 H 2 3 N O 2 114 
5e O C H 3 H C 2 H 5 H 49 C 2 1 H 2 5 N 0 2 99.5 
5f H O C H 3 C 2 H 5 H 60 C 2 1 H 2 5 N 0 2 oil 
5g O C H 3 H C 2 H 5 H 55 C 2 2 H 2 7 N 0 2 81.5 
5h H O C H 3 C 3 H 7 H 45 C 2 2 H 2 7 N 0 2 oil 
trans-5ic O C H 3 H C3H7 C H 3 15 C 2 0 H 2 3 N O 2 158.5 
cis-5id O C H 3 H H C H 3 36 C 2 0 H 2 3 N O 2 86.5 
transSk0 H O C H 3 H C H 3 17 C 2 0 H 2 3 N O 2 oil 
c/5-5kd H O C H 3 H C H 3 34 C 2 0 H 2 3 N O 2 118 
fra/i$-51c O C H 3 H H C 2 H 5 18 C 2 1 H 2 5 N 0 2 106 
C15-51d O C H 3 H H C 2 H 3 32 C 2 1 H 2 5 N 0 2 oil 
fraiis-5mc O C H 3 H H C 3 H 7 15 C 2 2 H 2 7 N 0 2 109 
c«-5m d O C H 3 H H C 3 H 7 36 C 2 2 H 2 7 N 0 2 oil 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Recrystallized from M e O H 
c Trans refers to the linkage of B and C rings 
d Cis refers to the linkage of B and C rings 
(2 bar, flow rate 3-4 ml/min). A l l [a] values refer to 22°C. 
(+)-trans-6\: ka = 1.2; [ a ] 3 6 5 = + 790 ± 60, [ a ] 4 3 6 = +400 ± 40, [ a ] 5 4 6 = +210 ± 30, 
[ a ] 5 7 8 = + 180 ± 30 (c = 1.1 mg/ml; C H 3 C N ) ; P b = 1.0. 
(-)-trans-6\: k = 2.1; [ a ] 3 6 5 = -670 ± 50, [ a ] 4 3 6 = -360 ± 40, [ a ] 5 4 6 = -170 ± 30, 
[ a ] 5 7 8 = -150 ± 30 (c = 1.1 mg/ml; C H 3 C N ) ; P ^ 0.83. 
(+)-trans-6m: k = 1.0; [ a ] 3 6 5 = +930 ± 100, [ a ] 4 3 6 = +460 ± 70, [ a ] 5 4 6 = +230 ± 50, 
[ a ] 5 7 8 = +200 ± 50, [ a ] 5 8 9 = +200 ± 50 (c = 0.6 mg/ml; C H 3 C N ) ; P = 1.0. 
(-)-trans-6m: k = 1.7; [ a ] 3 6 5 = -670 + 60, [ a ] 4 3 6 = -340 ± 40, [ a ] 5 4 6 = -190 ± 30, 
[ a ] 5 7 8 = -170 ± 30, [ a ] 5 8 9 = -150 ± 30 (c = 0.8 mg/ml; C H 3 C N ) ; P = 0.98. 
ak is the capacity factor of the d- and 1-enantiomers; k = (t{ - t0)/t0, where t{ = retention 
time and t0 = void volume elution time. 
b Opt ica l purity, calculated from a plot of rotation angle a versus U V absorbance 
according to Mannschreck et al. (1982). 
Binding affinities for steroid hormone receptors 
Affinities for estrogen (von Angerer et al., 1984) and progesterone receptors (Theofan & 
Notides, 1984) were determined with calf uterine cytosol as receptor source. Fresh calf 
uteri, stored in ice-cold saline, were freed of adherent fat and connective tissue at 4°C. 
After addition of the relevant buffer (10 mM Tris, 1.5 mM E D T A , 3 mM N a N 3 , p H 7.4, 
for E R , 10 mM Tris, 1.5 mM E D T A , 0.25 M sucrose, p H 7.4, for PR) the uteri were 
Table IV Diacetoxy-7,llb,12,13-tetrahydro-6//-dibenzo[ö>/]quinolizines 6 
Compound R1 R2 R3 R4 Formula* m.p. (°C) RBAb (ER) 
6a O C O C H 3 H H H C 2 1 H 2 1 N 0 4 153 0.3 
6b H O C O C H 3 H H C 2 1 H 2 1 N 0 4 120 0.4 
6c O C O C H 3 H C H 3 H C 2 2 H 2 3 N O 135.5 5.4 
6d H O C O C H 3 C H 3 H C 2 2 H 2 3 N 0 4 129 5.8 
6e O C O C H 3 H C 2 H 5 H C 2 3 H 2 5 N 0 4 134.5 6.0 
6f H O C O C H 3 C 2 H 5 H C 2 3 H 2 5 N 0 4 99.5 8.7 
6g O C O C H 3 H C 3 H 7 H C 2 4 H 2 7 N 0 4 81 10.5 
6h H O C O C H 3 C 3 H 7 H C 2 4 H 2 7 N 0 4 92 6.8 
trans-6\ O C O C H 3 H H C H 3 C 2 2 H 2 3 N 0 4 141.5 7.8 
cis~6\ O C O C H 3 H H C H 3 C 2 2 H 2 3 N 0 4 134.5 0.3 
trans-6k H O C O C H 3 H C H 3 C 2 2 H 2 3 N 0 4 92 5.8 
cis-6k H O C O C H 3 H C H 3 C 2 2 H 2 3 N 0 4 118 0.2 
trans-6\ O C O C H 3 H H C 2 H 5 C 2 3 H 2 5 N 0 4 129.5 8.3 
trans-(+)-6\ O C O C H 3 H H C 2 H 5 C 2 3 H 2 5 N 0 4 57 6.7 
trans-{—)-6\ O C O C H 3 H H C 2 H 5 C 2 3 H 2 5 N 0 4 58 10.8 
c/s-61 O C O C H 3 H H C 2 H 5 C 2 3 H 2 5 N 0 4 104 0.2 
trans-6m O C O C H 3 H H C3H7 C 2 4 H 2 7 N 0 4 123 2.5 
trans-(+)-6m O C O C H 3 H H C 3 H 7 C 2 4 H 2 7 N 0 4 45 2.2 
trans-(—)-6m O C O C H 3 H H C 3 H 7 C 2 4 H 2 7 N 0 4 46 3.0 
cis-6m O C O C H 3 H H C 3 H 7 C 2 4 H 2 7 N 0 4 92 0.1 
a Analyzed for C and H within ± 0 . 4 % of the calculated values 
b Relative binding affinity for the calf uterine estrogen receptor = ratio of molar concentration of 17ß-
estradiol (E2) and inhibitor required to decrease the amount of bound [3H]E2 by 50%, x 100 
Table V 1 H - N M R Data of 9-acetoxy-7,llb,12,13-tetrahydro-6//-dibenzo[fl,/]quinolizines 6 
Compound o [p.p.m.] (recorded in CDCl3 with TMS as internal standard) 
6a 1.80 (mc; 1H, H-12ax), 2.25 (mc; 1H, H-12eq), 2.25 (s; 3H,-CO-CH 3 ), 2.30 (s; 
3H,-CO-CH 3 ) , 2.88 (mc; 4H,-CH 2-), 3.26 (mc; 1H, H-6ax), 3.88 (mc; 1H, H -
6eq), 4.45 (dd, JLL2 = 2.5/9Hz; 1H, H- l lb ) , 6.70-7.05 (m; 5H, ArH), 7.30 (d, 
JLL2 = 9Hz; 1H, ArH) 
6b 2.23 (mc; 2H, H-12), 2.25 (s; 3H,-CO-CH 3 ) , 2.30 (s; 3H,-CO-CH 3 ), 2.65-3.40 
(m; 5H, -CH 2 , H-6ax), 3.93 (mc; 1H, H-6eq), 4.40 (dd, JLL2 = 2/9Hz; 1H, H -
11b), 6.25 (dd, JLL2 = 3/9Hz; 1H, ArH), 6.45 (d, J 1 / 2 = 3Hz; 1H, ArH) , 6.60-
7.10 (m; 3H, ArH) , 7.20 (d, / = 9Hz; 1H, ArH) 
6c 1.15 (d, / = 6Hz; 3H,-CH 3 ), 1.90-2.45 (m; 2H, H-12), 2.25 (s; 3H,-CO-CH 3 ) , 
2.30 (s; 3H,-CO-CH 3 ) , 2.65 ( A B X , J AX/AB = 2/16Hz; 1H, H-7eq), 2.80-3.10 
(m; 2H, H-13), 3.25 ( A B X , J B X / B A = 5/16Hz; 1H, H-7ax), 4.10-4.50 (m; 2H, 
H-6, H- l lb ) , 6.65-7.40 (m; 6H, Arh) 
6d 1.05 (d, J = 6Hz; 3H, CH 3 ) , 1.65-2.35 (m; 2H, H-12), 2.20 (s; 3H,-CO-CH 3 ) , 
2.25 (s; 3H-CO-CH 3 ), 2.55 ( A B X , J AX/AB = 2/16Hz; 1H, H-7eq), 2.70-3.05 (m; 
2H, H-13), 3.15 ( A B X , J B X I B A = 6/16Hz; 1H, H-7ax), 4.10-4.50 (m; 2H, H-6, 
H- l lb ) , 6.40 (dd, JLL2 = 2/9Hz; 1H, ArH), 6.70-7.00 (m; 3H, ArH) , 7.20 (d, / 
= 9Hz; 1H, ArH) 
Table V (continued) 











0.90 (t, / = 7.5Hz; 3H, CH 3 ) , 1.20-1.60 (m; 2H,-CH 2 -CH 3 ) , 1.80-2.40 (m; 2H, 
H-12), 2.15 (s; 3H,-CO-CH 3 ) , 2.20 (s; 3H,-CO-CH 3 ) , 2.65 ( A B X , J A X I A B = 0.5/ 
16Hz; 1H, H-7eq), 2.70-3.05 (m; 2H, H-13), 3.15 ( A B X , J B X I B A = 5/16Hz; 1H, 
H-7ax), 4.10 ( A B X , J X A I X B = 0.5/5Hz; 1H, H-6), 4.35 (dd, J 1 2 = 2/9Hz; 1H, 
H- l lb ) , 6.50-7.40 (m; 6H, ArH) 
0.90 (t, / = 7.5Hz; 3H,-CH 2 -C/ / 3 ) , 1.10-1.65 (m; 2H,-CH 2 -C/ / 3 ) , 1.75-2.40 (m; 
2H, H-12), 2.20 (s; 6H,-CO-CH 3 ) , 2.60 ( A B X , J A X I A B = 2/16Hz; 1H, H-7eq), 
2.75-2.90 (m; 2H, H-13), 3.10 ( A B X , J B X I B A = 6/16Hz; 1H, H-7ax), 3.90 
( A B X , JXAIXB = 2/6Hz; 1H, H-6), 4.45 (dd, / = 3/9Hz, 1H, H- l lb ) , 6.30 (dd, 
J 1 / 2 = 3/9Hz; 1H, ArH) , 6.45 (d, / = 3Hz; 1H, ArH) , 6.70-7.00 (m; 3H, ArH), 
7.20 (d, / = 9Hz; 1H, ArH) 
0.90 (t, / = 7Hz; 3H,-CH 2 -C/ / 3 ) , 1.25-1.75 (m; 4H, -C/ / 2 -C/ / 2 -CH 3 ) , 1.90-2.40 
(m; 2H, H-12), 2.20 (s; 3H,-CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ) , 2.65 ( A B X , 
JAXIAB = 0.5/16Hz; 1H, H-7eq), 2.75-3.00 (m; 2H, H-13), 3.10 ( A B X , J B X / B A 
= 5/16Hz; 1H, H-7ax), 4.10 ( A B X , J A B I X B = 0.5/5Hz; 1H, H-6), 4.40 (dd, J M 
= 2/7Hz; 1H, H- l lb ) , 6.70-7.40 (m; 6H, ArH) 
0.85 (t, / = 6Hz; 3H,-CH 2 -C/ / 3 ) , 1.05-1.75 (m; 4H, -C/ / 2 -C/ / 2 -CH 3 ) , 1.80-2.45 
(m; 2H, H-12), 2.25 (s; 6H,-CO-CH 3 ) , 2.65 ( A B X , J A X I A B = 2/16Hz; 1H, H -
7eq), 2.75-3.00 (m; 2H, H-13), 3.15 ( A B X , J B X I B A = 6/16Hz; 1H, H-7ax), 4.10 
( A B X , JJXA/XB = 2/6Hz; 1H, H-6), 4.45 (dd, J 1 2 = 3/9Hz; 1H, H- l lb ) , 6.40 
(dd, J Y 2 = 3/9Hz; 1H, ArH) , 6.55 (d, / = 3Hz; 1H, ArH) , 6.80-7.15 (m; 3H, 
ArH), 7.30 (d, / = 9Hz; 1H, ArH) 
0.70 (d, / = 7Hz; 3H,-CH 3 ) , 2.20 (s; 3H,-CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ) , 2.50 
( A B X , J X A I X B = 5/6Hz; 1H, H-12), 2.60 ( A B X , J A X I A B = 0.5/16Hz; 1H, H -
13eq), 2.70-3.10 (m; 3H, H-6ax, H-7), 3.35 ( A B X , J B X I B A = 6/16Hz, 1H, H -
13ax), 4.00 (mc; 1H, H-6eq), 4.45 (d, / = 0.5Hz; 1H, H- l lb ) , 6.65-7.35 (m; 
6H, ArH) 
1.15 (d, / = 6Hz; 3H,-CH 3 ) , 2.20 (s; 3H,-CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ) , 2.30 
( A B X , J A X / A B = 3/16Hz; 1H,H-I3eq), 2.55 ( A B X , J X A I X B = 3/5Hz; 1H, H-12), 
2.65 (mc; 1H, H-7), 2.80 ( A B X , J B X I B A = 5/16Hz; 1H, H-13ax), 3.00-3.60 (m; 
2H, H-6ax, H-7), 3.90-4.25 (m; 2H, H-6eq, H- l lb ) , 6.50 (d, / = 3Hz; 1H, 
ArH) , 6.56 (d, / = 3Hz; 1H, ArH) , 6.65-7.35 (m; 6H, ArH) 
0.70 (d, / = 6.5Hz; 3H,-CH 3 ) , 2.25 (s; 6H,-CO-CH 3 ) , 2.30 ( A B X , J X A / X B =0.5/ 
6Hz; 1H, H-12), 2.55 ( A B X , J A X I A B = 0.5/16Hz; 1H, H-13eq), 2.65-3.10 (m; 
3H, H-6ax, H-7), 3.30 ( A B X , J B X I B A = 6/16Hz-; 1H,H-I3ax), 4.00 (mc; 1H, H -
6eq), 4.45 (d, / = 0.5Hz; 1H, H- l lb ) , 6.35 (dd, J L 2 = 3/9Hz; 1H, ArH), 6.45 
(d, / = 3Hz; 1H, ArH), 6.75-7.10 (m; 3H, ArH) , 7.25 (d, / = 9Hz; 1H, ArH) 
1.15 (d, / = 6.5Hz; 3H, CH 3 ) , 2.25 (s; 6H,-CO-CH 3 ) , 2.35 ( A B X , J A X I A B =0.5/ 
16Hz; 1H, H-13eq), 2.45 ( A B X , J X A I X B = 0.5/5Hz; 1H, H-12), 2.45-3.30 (m; 
3H, H-6ax, H-7), 3.45 ( A B X , J B X I B A = 5/16Hz; 1H, H-13ax), 4.00 (mc; 1H, H -
6eq), 4.20 (d, / = 3Hz; 1H, H- l lb ) , 6.35 (dd, J 1 2 = 3/9Hz; 1H, ArH) , 6.55 (d, 
/ = 3Hz; 1H, ArH) , 6.70-7.00 (m; 3H, ArH) , 7.25 (d, / = 9Hz; 1H, ArH) 
0.75 (t, / = 7.5Hz; 3H,-C 2 -C// 3 ) , 1.00-1.20 (m; 2H,-C/ / 2 -CH 3 ) , 2.20 (s; 3H,-
CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ) , 2.35 ( A B X , J X A I X B = 0.5/6Hz; 1H, H-12), 
2.70 ( A B X , J A X I A B = 0.5/16Hz; 1H, H-13eq), 2.80-3.05 (m; 3H, H-6ax, H-7), 
3.20 ( A B X , J B X I B A = 6/16Hz-; 1H, H-13ax), 3.93 (m; 1H, H-6eq), 4.45 (d, / = 
0.5Hz; 1H, H- l lb ) , 6.50-7.35 (m; 6H, ArH) 
1.05 (t, / = 7.5Hz; 3H,-CH 2 -C/ / 3 ) , 1.30-1.70 (m; 2H,-CH 2 -CH 3 ) , 2.15 (s; 3H,-
CO-CH 3 ) , 2.20 (s; 3H,-CO-CH 3 ) , 2.40 ( A B X , J X A I X B = 0.5/6Hz; 1H, H-12), 
2.60 ( A B X , J A X I A B = 0.5/16Hz; 1H, H-13eq), 2.75-3.35 (m; 3H, H-6ax, H-7), 
3.45 ( A B X , JBXIBA = 4/16H; 1H, H-13ax), 4.10 (mc; 1H, H-6-eq), 4.30 (d, / = 
2Hz; 1H, H- l lb ) , 6.60-7.40 (m; 6H, ArH) 
Table V (continued) 
Compound 8 fp.p.m.J (recorded in CDCl3 with TMS as internal standard) 
trans-6m 0.75 (t, / = 6Hz; 3H,-CH 2 -C/ / 3 ) , 0.85-1.50 (m; 4H, -C/ / 2 -C/ / 2 -CH 3 ) , 2.20 (s; 
3H,-CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ), 2.35 ( A B X , J X A / X B = 0.5/6Hz; 1H, H -
12), 2.75 ( A B X , J A X I A B = 0.5/16Hz; 1H, H-13eq), 2.85-3.15 (m; 3H, H-6ax, H -
7), 3.25 ( A B X , J B X / B A = 6/16Hz; 1H, H-13ax), 3.95 (mc; 1H, H-6eq), 4.45 (d, / 
= 0.5Hz; 1H, H- l lb ) , 6.60-7.35 (m; 6H, ArH) 
cis-6m 1.00 (t, / = 6Hz; 3H,-CH 2 -C/ / 3 ) , 1.20-1.70 (m; 4H,-C/ / 2 -C/J 2 -CH 3 ) , 2.20 (s; 
3H,-CO-CH 3 ) , 2.25 (s; 3H,-CO-CH 3 ), 2.35 ( A B X , J A X I A B = 2/16Hz; 1H, H -
13eq), 2.50-3.20 (m; 4H, H-6ax, H-12, H-7), 3.45 ( A B X , J B X I B A = 5/16Hz; 1H, 
H-13ax), 4.03 (mc; 1H, H-6eq), 4.30 (d, / = 3Hz; 1H, H- l lb ) , 6.70-7.40 (m; 
6H, ArH) 
homogenized by treatment with a ultraturrax mixer ( I K A , F R G ) and a glass-in-glass 
homogenizer (Potter S; Braun, Germany) at 4°C. Lipids were separated by centrifuga-
tion at 700 g and discarded. The homogenate was centrifuged at 105000 g for 100 min 
(0°C). The supernatant (cytosol) was then used for determining the affinity of com-
pounds for the receptor. The protein concentration of the cytosol was ~15 mg/ml 
leading to a final concentration of 3 mg/ml in the assay. 
Relative binding affinities ( R B A ) were determined by the dextran-coated charcoal 
( D C C ) method: 100 |xl aliquots of the cytosol were incubated with 100 |JL1 (1 nivi) of 
[3//]estradiol (ER) or [3//]Org 2058 (PR) and different concentrations of the test 
compounds at 0 -4°C for 16 h (ER) or 2 h (PR). Non-specific radioligand binding was 
determined by a parallel incubation containing 2 | X M of estradiol (ER) or progesterone 
(PR) . After incubation, dextran-coated charcoal suspension (0.625% dextran 80.000, 
1.25% Norit A in the relevant buffer) was added and the mixture was shaken for 90 min 
(ER) or 10 min ( A R , PR) at 0 -4°C . After centrifugation for 10 min at 800 g, the 
radioactivity of a 100 uJ supernatant aliquot was counted. The percentage of bound 
radioligand was plotted against the concentration of unlabeled test compounds. A 
standard curve of unlabeled estradiol or progesterone was included in each assay. Four 
to six concentrations of each competitor were tested. They were chosen to provide a 
linear portion on a semilogarithmic plot crossing the point of 50% competition. The 
R B A was calculated as the ratio of the molar concentrations of hormone and test 
compound required to decrease the amount of bound radioactivity by 50%, multiplied by 
100. 
In vitro determination of cytostatic activity 
Hormone-sensitive human M C F - 7 breast cancer cells were obtained from American 
Type Culture Collection (Rockville, M D , U S A ) . Cells were grown in improved Minimal 
Essential Medium ( M E M ) , as modified by Richter et al. (1972) (Biochrom, Berl in, 
Germany), supplemented with glutamine (0.3 g/1), gentamycin (60 mg/1 and 10% new-
born calf serum (NCS) (Gibco) or charcoal-treated N C S (CCS). C C S was prepared by 
incubation of 500 ml N C S with a dextran-coated charcoal pellet (Scholl et al, 1983) for 4 
h in a shaker at 0 -4°C . The procedure was repeated with a fresh pellet. After each 
incubation, the charcoal was removed by centrifugation. The serum was sterilized 
through a 0.20 |xm filter (Sartorius, Gött ingen, Germany) and stored at - 2 0 ° C . A l l of 
the experiments were performed in the presence of phenol red. Cells were grown in a 
humidified incubator in 5% C 0 2 at 37°C. Two weeks before the start of the experiment, 
cells were switched from N C S to C C S and received two additional media changes before 
they were harvested with 0.05% trypsin-0.02% E D T A in 0.15 M N a C l . 
A t the start of the experiment, the cell suspension was transferred to 96-well microtiter 
plates (100 |xl/well). After growing them for 2-3 days in a humidified incubator with 5% 
C 0 2 at 37°C, medium was replaced by one containing the drug. Control wells (16/plate) 
contained 0.1% of ethanol that was used for the preparation of the stock solution. The 
initial cell density was determined by addition of vinblastin (10~7 M ) . After incubation for 
7 days, the medium was removed and 100 |xl of glutaric aldehyde in PBS (1%) were 
added for fixation. After 15 min, the solution of aldehyde was decanted. Cells were 
stained by treating them for 25 min with 100 |ml of an aqueous solution of crystal violet 
(0.02%). After decanting, cells were washed several times with water to remove ad-
herent dye. After addition of 100 JULI of ethanol (70%), plates were gently shaken for 1 h. 
Optical density of each well was measured in a microplate autoreader E L 309 (Bio-tek) 
at 578 nm. Data calculation and analysis were performed with a P C (Reile et al., 1990). 
Hormone-independent M D A - M B 231 human mammary tumor cells were obtained 
from American Type Culture Collection. Cells were grown in McCoy 5a medium 
(Boehringer Mannheim, Germany) supplemented with 10% N C S and gentamycin (40 
|xg/ml). Cytostatic activity was determined in a microtiter plate assay as described for 
M C F - 7 cells with one exception: the incubation period was 2-3 days. 
Immature mice uterine weight tests 
Immature female mice (20 days old, N M R I strain) from Charles River Wiga (Sulzfeld, 
Germany) were randomly divided into groups of 6-10 animals. To determine estrogenic 
activity, compounds were dissolved in polyethylene glycol/0.9% saline (7:3; 100 |xl/ 
animal) and injected subcutaneously on three consecutive days. Control animals re-
ceived the vehicle alone. Twenty-four hours after the last injection, the animals were 
killed by cervical dislocation and weighed. Uteri were dissected free of fat and fixed to 
Bouin solution (saturated aqueous picric acid, 34%; formaldehyde, glacial acetic acid 
15:5:1 by volume) for 2 h. Uteri were freed from connective tissue, washed with ethanol, 
dried at 100°C for 24 h, and weighed. The relative uterus weight was calculated by the 
formula: uterine dry weight (mg)/body weight (g), multiplied by 100. 
To determine the antiestrogenic activity, the same protocol was used with one modifi-
cation: Increasing doses of the compounds were injected together with a standard dose 
(0.4 Uvg) of estrone. The inhibition (%) of the estrone-stimulated uterine growth was 
estimated by the formula: 100 - [ ( W S , T - W V ) / ( W S - W v ) x 100] ( W S f T = rel. uterus 
weight of animals treated with estrone standard (0.4 |xg) + text compound; W v = rel. 
uterus weight of control animals; W s = rel. uterus weight of animals treated with estrone 
standard). 
Transplanted MXT-mammary tumors of the mouse 
The M X T - M 3.2 mammary tumors were generously provided by D r A . E . Bogden, E G & 
G Mason Research Institute, Worcester, M A , U S A . Hormone-sensitive tumors grew for 
4-5 weeks in the host animals before transplantation. Tumor pieces of 1 m m 2 were 
serially transplanted into 8- to 10-week-old female B 6 D 2 F j mice, obtained from Charles 
River Wiga (Sulzfeld, Germany). Animals were assigned randomly in groups of 10 and 
treatment was started 24 h after transplantation. Drugs were dissolved in olive oil and 
administered subcutaneously on Monday, Wednesday and Friday. After a 5-week period 
of treatment, animals were killed and autopsied. Tumors were removed and weighed. 
The uterine dry weight was determined as described above. The change of body weight 
between start and end of therapy was recorded in order to detect obvious toxicity. 
Significance of differences was determined by the U test according to Wilcoxon, modified 
by Mann and Whitney. 
Results 
Chemistry 
The synthesis of the tetracyclic dibenzo[a,/]quinolizine system involved two ring closure 
reactions (Scheme 1): The starting amides 3 for the first cyclization were obtained by 
reacting l-alkyl-2-(3-methoxyphenyl)ethylamines 1 with the respective (bromomethoxy-
phenyl)propionic acid chloride. The isoquinoline ring was formed by the Bischler-
Napieralski reaction using P O C l 3 in M e C N . The dihydroisoquinolines were isolated as 
hydrochlorides. The free bases were reduced with sodium boronhydride to yield the 1-
phenethyl-tetrahydroisoquinolines 4. Derivatives with an alkyl group in a-position to the 
heterocycle were obtained as mixtures of diastereomers which were not resolved. A n 
alkyl group next to the nitrogen can give rise to the formation of diastereomeric cisltrans-
isomers. The reduction, however, was highly stereoselective leading predominantly to 
the ds-isomers 
The second ring closure reaction was accomplished by treating the bromo-substituted 
phenethyl-tetrahydroisoquinolines 4a-m with sodium (methylsulfinyl)methanide (Corey 
& Chaykorsky, 1965) as strong base. The cyclization occurred via a benzyne inter-
mediate as demonstrated by converting both o- and m-bromo derivatives to the same 
tetracycle (Kano et al., 1976). In the case of diastereomeric tetrahydroisoquinolines the 
respective isomers of the tetrahydro-dibenzo[«,/]quinolizines 5i-m were formed which 
could be separated by column chromatography. Due to the nitrogen as bridge head atom 
the tetrahydroquinolizine ring connection can easily adopt two different orientations 
which correspond to eis- and trans-decalin respectively. When a substituent had been 
introduced into position 12, the orientation in which this substituent holds an axial 
position is energetically favoured. Thus, these diastereomers were described as eis I 
trans-isomtrs referring to the steric arrangement of the ring connection. Structural 
1a : R3 = H 2a OCH3 H H H Br 3 a - m 
1b : R3 = CH 3 2b H OCH3 H Br H 
1 c : R 3 = C 3 H ,
 2 C 0 C H 3 H C H 3 H B r 
3 2d H OCH3 CH 3 Br H 
1d : R = C 3 H 7 2 e 0 C H 3 |_| C 2 h , 5 H B r 
Scheme 1 
assignments of the separated isomers were made mainly by j H N M R spectroscopy using 
the N O E technique. 
In the case of the 6-alkyl derivatives 5c-h only one isomer was isolated which has be 
assumed to be ds-configured in respect to the substituents at C-6 and C - l l b of the 
tetracycle. The substituent at C-6 adopts an axial position which forces the quinolizine 
system into a trans orientation of the central ring connection. The minimum energy of 
the structure with equatorial substituents is about 1.5 kcal/mol higher than the one with 
axial groups and leads to a nearly perpendicular arrangement of the two aromatic rings. 
After ether cleavage of 5, the free hydroxy derivatives were converted into the 
corresponding acetates 6 because the phenolic compounds are sensitive to autoxidation. 
In order to study the interaction of the 12-alkyl derivatives with biological targets in 
detail we separated the enantiomers of both diastereomeric forms of 61 and 6m by liquid 
chromatography on triacetyl cellulose (Koller et al., 1983) and characterized them. The 
assignment (+) and (—) for the enantiomers refers to the sign of optical rotation at 578 nm. 
Biochemical and biological properties 
A prerequisite of a selective action is the ability of a drug to bind to a target protein. 
Thus, we determined the binding affinities of all of the acetoxy derivatives for the calf 
uterine estrogen receptor using the D C C method as described (von Angerer et al., 1984). 
The relative binding affinities ( % R B A ) are given as the ratio of the molar concentrations 
of 17ß-estradiol and tetrahydro-benzo[a,/]quinolizine required to decrease the 
amount of receptor-bound [ 3 H]17ß-estradiol by 50%, multiplied by 100. 
A l l derivatives showed R B A values > 1 except those lacking alkyl groups in both 
positions 6 and 12 or having a ds-structure in relation to the central ring connection 
(Table I V ) . The importance of short alkyl groups in the central part of the molecule has 
been recognized in all non-steroidal structures which bind to the estrogen receptor. Like 
in other classes of compounds (von Angerer et al., 1984) a chain length of two or three 
carbon atoms appears to be the optimum. No difference in receptor binding was noticed 
between derivatives with the second oxygen function at C-2 and the 3-acetoxy series. A 
striking difference in binding affinity was observed between the trans- and the eis-
isomers. The ds-orientation of central ring connection leads to the right-angled bend of 
the molecule which can no longer mimic the steroidal structure of estradiol. When the 
racemic mixtures of the frarcs-quinolizines 61 and m had been separated, the enantiomers 
displayed rather similar binding affinities. This observation is in accord with previous 
findings in the indoloisoquinoline series in which the enantiomers of the 6-alkyl deriva-
tives did not differ very much in their R B A values (Ambros et al., 1989). 
A number of compounds with high binding affinity for the estrogen receptor were also 
tested for affinity for the progesterone receptor in order to evaluate their molecular 
selectivity. With most of these derivatives, the R B A values for the progesterone receptor 
were lower by more than one order of magnitude than those for the estrogen receptor. 
However, dibenzoquinolizines with the acetoxy function in position 2 and the alkyl group 
at C-6 (6d, f, g) exhibited binding affinities greater then 1 which are close to those for the 
estrogen receptor (Table V I ) . 
Preliminary studies with the tetrahydro-dibenzo[a,/]quinolizines 6a-m in estrogen-
sensitive M C F - 7 breast cancer cells revealed four derivatives with significant cytostatic 
activities at 10" 5 M (6f, h, trans-6\ and trans-6m). These compounds were also tested at 
lower concentrations together with the (+) and (—)-enantiomers of both active trans-
isomers (Table VII ) . The most potent agent was trans-6\ with an IC 5 0 -value of about 5 X 
10~ 7 M . The enantiomers of this racemate did not differ significantly in their cytostatic 
activity. There was only a slight general superiority of the dextro rotatory form. 
Table VI Binding affinity of compounds 6 for the progesterone 
receptor 
Compound R1 R2 R3 R4 RBA* (PR) 
6c O C O C H 3 H C H 3 H <0.01 
6d H O C O C H 3 C H 3 H 3.1 
6e O C O C H 3 H C 2 H 5 H 0.1 
6f H O C O C H 3 C 3 H 7 H 1.8 
6g O C O C H 3 H C 3 H 7 H 0.1 
6h H O C O C H 3 C 3 H 7 H 1.2 
trans-6\ O C O C H 3 H H C H 3 0.1 
trans-6\ O C O C H 3 H H C 2 H 5 0.1 
trans-6m O C O C H 3 H H C 3 H 7 0.2 
a Relative binding affinity for the calf uterine progesterone receptor = 
ratio of molar concentrations of progesterone and inhibitor, required to 
decrease the amount of bound [3H]Org 2058 by 50%, x 100 
Table VII Effect of compounds 6g, 6h, trans-6\ and trans-6m on the growth of 
MCF-7 and MDA-MB-231 mammary tumor cells 
MCF-7 MDA-MB-231 
Compound 5 x 10~7 1 x 10'6 5 x 10~6 1 x 10~5 1 x 10~5 
% TIC % TIC % TIC % TIC % TIC 
6f 70 + 12 40 ± 10b 18 + 5 77 ± l l b 
6h 80 ± 9 44 ± 8
b 11 ± 7 b 70 + l l b 
trans-6\ 42 + 14b 41 ± 14b 28 + 12b 2 ± 5 b 85 ± l l
c 
trans-(+)-6l 35 + 17b 29 ± 13b 16 + 10b - 3 ± 2 b 
trans-(—)-6\ 49 ± 19
b 46 ± 15a 30 ± l l b 1 3 ± 1 0 b 
trans-6m 73 ± 24
b 52 ± 1 7 b 30 ± 13b 7 ± 7
b 80 ± 9c 
trans-(+)-6m 81 + 14 44 + 14 21 ± 14
b - 2 ± 3 b 
trans-(-)-6m 76 + 19 70 + 27 42 ± 19b 11 ± 5
b 
Tamoxifen 83 ± 10 52 ± 13
b 31 ± l l b 7 ± 1 0 b 
a Estrogen receptor negative cells 
bSignificant inhibition; P < 0.01 
cSignificant inhibition; P < 0.05 
In order to exclude non-specific cytostatic or cytotoxic effects we tested the active 
compounds in estrogen receptor negative M D A - M B 231 human breast cancer cells. Only 
at the highest concentration (10 JXM) was a weak inhibitory effect observed. 
The high binding affinities of 6f, trans-6\ and trans-6m and their cytostatic activity in 
M C F - 7 cells prompted us to study them in vivo using the M X T mouse mammary tumor 
model. A t a dose of 3 x 10 mg/kg body weight per week, the inhibitory effect was not 
significant. When the dose had been doubled trans-6\ inhibited tumor growth by 78% 
(Table VIII) . Since the uterus weights of the treated animals were somewhat higher than 
those of control animals we determined estrogenic and antiestrogenic activity of these 
drugs in the immature mouse uterine weight test. Compounds 6f and 6h displayed dose 
response curves typical for partial estrogen antagonists (Table IX) . The maximum 
inhibition of estrone-stimulated uterine growth was about 60%. Derivatives trans-6m 
and, especially, trans-6\ showed strong but transient antagonistic activity. With low doses 
(10-50 |xg/animal) of trans-6\, the effect of estrone was nearly completely overcome. A t 
high doses, however, the estrogenic component became dominant. 
Table VIII Effect of trans-6\ and trans-6m, tamoxifen, and ovariectomy on the growth of 
hormone dependent M X T mammary tumors and uteri of BDFj mice 










Control 927 (111-2230) 100 100 1.5 
Ovariectomy 5 (0-10) 0.5e 17e 1.2 
Tamoxifen 8.8 140 (50-610) 15e 79 1.4 
trans-6\ 10 760 (12-1890) 82 96 1.8 
trans-6m 10 597 (50-1080) 64 132 2.0 
Control 443 (176-1886) 100 100 0.6 
Ovariectomy 8 (5-42) 2 e 25e -0.14 
Tamoxifen 8.8 107 (41-216) 24e 100 -0.15 
trans-6\ 20 96 (20-872) 22f 126f 0.6 
6f 20 235 (83-868) 56 115 0.6 
aDose/kg body weight, dissolved in olive oil and administered three times per week subcutaneously 
bDetermined after 5 weeks of treatment; 6 animals per group 
c Ratio of uterine dry weights of treated and control animals 
d Change of body weight between days 1 and 6 to detect acute toxic effects 
eSignificant inhibition; P < 0.01 (U-test) 
Significant inhibition; P < 0.05 (U-test) 
Discussion 
Various tetracyclic alkaloids such as berbine derivatives have been shown to possess 
cytostatic activity (Zee-Cheng & Cheng, 1973). In order to achieve a more selective 
action of these substances we modified them in such a way that they bind to specific 
biochemical structures present in malignant cells. Receptors for steroid hormones such 
as estrogens are found in the majority of advanced mammary carcinomas and can be 
used as targets. A prerequisite for high binding affinity for estrogen receptors is the 
presence of two oxygen functions such as hydroxy or acetoxy groups in appropriate 
positions of the tetracycle. 
Previous studies in this series of tetrahydro-dibenzo[«,/]quinolizines and in related 
classes of compounds (von Angerer & Prekajac, 1986; Ambros et al., 1989; Polossek et 
al., 1992; von Angerer et al., 1992) (Structures 2) have shown that position 9 for the first 
oxygen function and either position 2 or 3 for the second one are most favorable for 
receptor binding. The differences between the latter two positions are not very pro-
nounced. More important was the introduction of a short alkyl group in position 6 or 12 
in order to enhance the lipophilicity in the central part of the molecule. Unexpectedly, 
the basic nitrogen atom which belongs to a tertiary aniline structure did not lower the 
binding affinity of this system as shown by comparison with analogous dibenzo[a,g]-
quinolizinones and indolo[2,/-a]isoquinolines (Polossek et al., 1992; von Angerer et al., 
1992). 
A n important feature of this partially saturated heterocyclic system is the presence of 
chiral centers. Since the interactions of drugs with their biological targets are usually 
characterized by a high degree of stereospecificity, we isolated the stereoisomers and 
studied them separately. The introduction of an alkyl substituent in position 12 gave rise 
to the formation of diastereomeric mixtures due to the chiral bridge head atom. Since the 
12-alkyl group in both isomers adopts the energetically favored axial position the 
arrangement of the ring connection in the quinolizine is either eis or trans. The eis-
Table IX Estrogenic and antiestrogenic activity of 9-acetoxy-
7,llb,12,13-tetrahydro-6//-dibenzo[fl,/|quinolizines 6 in the 
mouse uterine weight test 




Control 0 100 
Estrone 0.024 100 0 
6f 0.12 2 45e 
0.6 14e 62e 
3.0 14f 68e 
15.0 32e 62e 
6h 0.12 10 31e 
0.6 10f 58e 
3.0 24e 58e 
15.0 34e 50e 
trans-6\ 0.12 0 10 
0.6 15f 89e 
3.0 26f 89e 
15.0 76e 34f 
trans-6m 0.12 4 32f 
0.6 13 61e 
3.0 76e 48e 
15.0 100e 0 
aDose per animal, administered on three consecutive days s.c. 
b Calculated by the formula ( W y - W V ) / (W S - W v ) x 100 (W T = 
rel. uterus weight of treated animals; W v = rel. uterus weight of 
control animals; W s = rel. uterus weight of animals injected with 0.4 
|xg estrone/animal) 
c The U-test according to Wilcoxon, modified by Mann and Whitney, 
was used to determine significance 
dInhibition of estrone-stimulated uterine growth. Animals received the 
drug and estrone (0.4 |xg/animal) simultaneously 
Significant at P < 0.05 
Significant at P < 0.01 
isomers which are characterized by a bent structure of the molecule showed much lower 
binding affinities than the corresponding trans-isomers. When the enantiomers of the 
frans-derivatives were studied for receptor affinity no distinct differences were noticed. 
We had made a similar observation when we studied the enantiomers of 6-alkyl-
dihydroindolo[2,/-a]isoquinolines (Polossek et al., 1992). We were able to rationalize 
these findings by comparison with steroidal structures bearing a substituent at C - l l . 
Possibly, the position 12 of the dibenzoquinolizines corresponds to the position 11 of 
17ß-estradiol which is equivalent to carbon 6 in the indoloisoquinoline series (Polossek et 
al., 1992). This is in accord with results obtained with 6-alkyl-dibenzo[a,g]quinolizinones 
(von Angerer et al., 1992). Enantiomers of this type of compounds differed by one order 
of magnitude in binding affinity. This difference is expected if the 6-position is equivalent 
to the C-7 of estradiol. 
A l l of the derivatives with high binding affinities were studied for specific cytostatic 
activity in human M C F - 7 breast cancer cells. A strong inhibitory effect was observed 
with both the 12-ethyl and 12-propyl derivative with a ^^ -o r i en t a t i on of the central 
ring connection (trans-6\ and trans-6m). The effect was equivalent to that of the refer-
ence drug tamoxifen. When the respective enantiomers were studied, a somewhat higher 
activity was observed for the (-^-stereoisomers. But the differences were not so pro-
nounced as in the indoloisoquinoline series where the I C 5 0 values differed by one order 
lndolo[2,1 -a]isoquinoline Dibenzota^Jquinolizin-S-one 
Benzo[a]carbazole 17ß-Estradiol 
R = C H 3 , C 2 H g , CgH-y 
Structures 2 Structures of dibenzo[«,g]quinolizinones, indolo[2,l-tf]isoquinolines, 
benzo[a]carbazoles, and 17ß-estradiol 
of magnitude (Polossek et al., 1992). Despite their similarity in receptor binding, both 
classes of compounds differed considerably in their general cytostatic properties. Experi-
ments with estrogen receptor negative M D A - M B 231 breast cancer cells revealed that 
the dibenzoquinolizines require the estrogen receptor for a cytostatic action whereas 
the antitumor activity of the indoloisoquinolines was obviously not receptor-mediated 
(Polossek et al., 1992). 
Preliminary in vivo experiments with transplanted hormone-dependent M X T mouse 
mammary tumors showed antitumor activity for all of the compounds tested. However, 
at the applied doses this effect was not yet significant except for trans-61, which exhibited 
an antitumor effect similar to that of the antiestrogen tamoxifen (78% vs. 76%). The 
inhibition of tumor growth in this model can be a result of either antiestrogenic activity 
or estrogenic effects. In order to distinguish between these two possible modes of action 
we determined the endocrine properties of the compounds used in these tumor experi-
ments in the mouse uterine weight test. A l l of these derivates can be classified as mixed 
agonists/antagonists with strong antiestrogenic activity at low doses (up to 3 mg/kg body 
weight) but significant estrogenic effects at higher doses. This endocrine profile does not 
allow one to attribute the antitumor activity of these compounds to one or the other 
mechanism. The tetracyclic system of the dibenzo[a,/]quinolizines appears to be an 
appropriate structure for the design of antiestrogens but requires probably the intro-
duction of a functional side chain into position 6 or 12 such as an aminoalkyl group (von 
Angerer et al., 1990) or a carbamoylalkyl function (Wakeling & Bowler, 1988). 
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